Hear from a panel of experts discussing how to optimize the management of inherited blood disorders.
On Dec. 14, 2022, CMS released the Calendar Year (CY) 2024 Part C and D Policy and Technical
Proposed Rule. This proposed rule applies to Medicare Advantage (MA), Part D, Medicare cost plans,
and Programs of All-Inclusive Care for the Elderly (PACE).
Andrey Ostrovsky, MD, FAAP, and Lisa Palko, PharmD, discuss the ADHD landscape, challenges, and progress, including Akili's digital therapeutics value proposition as the first FDA-authorized prescription video game treatment.
Partnership Forum: This forum helped identify payer needs and current barriers that payer currently face regarding evidence for therapies approved through an expedited approval process. In addition, participants identified potential solutions to address evidence gaps.
On Nov.7, 2022, the Centers for Medicare & Medicaid Services (CMS) issued guidance about
the Inflation Reduction Act (IRA) changes to cost sharing requirements. The requirements are
effective April 1, 2023 for Part B drugs with prices increasing faster than inflation and July 1,
2023 for the monthly Part B cost-sharing cap for insulins.
The Medicare Program; Implementing Certain Provisions of the Consolidated
Appropriations Act, 2021 and other Revisions to Medicare Enrollment and Eligibility
Rules final rule implements certain provisions of the Consolidated Appropriations Act, 2021
(CAA) (P.L. 116-260) and is expected to be published in the Federal Register on Nov. 3, 2022.
On today's episode of PopHealth Week, our guest is Eddie Martucci, PhD, co-founder & CEO of Akili Interactive, a company getting to the root of cognitive impairment by creating personalized digital therapeutics engineered to directly improve cognitive impairments.
